Overexpression of RelA and P50 has been previously reported in laryngeal carcinoma and has been linked to tumor progression, therapy response, and prognosis [26–31], but the potential role of RelB as a biomarker of progression and survival is still under investigation. Here, RELB is linked to laryngeal carcinoma.